Spyre Therapeutics, Inc.

ADAGE CAPITAL PARTNERS GP, L.L.C. SYRE

Report date

3/31/2023

Quarter

2023 Q1

Filed

5/15/2023

Shares

1,500,000

Value ($000)

435

Weight

0.0%

2019 Q4 - 2023 Q1 (13 filings)

Shares History

History scope: non-option holdings only (PUT/CALL rows excluded).

All 13F Holders	Filing date	Value ($000s)	% of Holdings	Shares	Reporting period
2023 Q1	5/15/2023	435	0.0%	1,500,000	3/31/2023
2022 Q4	2/14/2023	675	0.0%	1,500,000	12/31/2022
2022 Q3	11/14/2022	789	0.0%	1,500,000	9/30/2022
2022 Q2	8/15/2022	758	0.0%	1,500,000	6/30/2022
2021 Q4	2/14/2022	4,750	0.0%	1,000,000	12/31/2021
2021 Q3	11/15/2021	27,825	0.1%	3,500,000	9/30/2021
2021 Q2	8/16/2021	21,225	0.0%	3,049,581	6/30/2021
2021 Q1	5/17/2021	23,349	0.0%	2,948,141	3/31/2021
2020 Q4	2/16/2021	23,547	0.1%	2,992,000	12/31/2020
2020 Q3	11/16/2020	21,213	0.1%	2,992,000	9/30/2020
2020 Q2	8/14/2020	26,751	0.1%	2,892,000	6/30/2020
2020 Q1	5/15/2020	6,844	0.0%	1,468,591	3/31/2020
2019 Q4	2/14/2020	11,220	0.0%	1,468,591	12/31/2019